Northern Trust’s Dianthus Therapeutics DNTH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $25.5M | Buy |
303,752
+96,506
| +47% | +$5.59M | ﹤0.01% | 1517 |
|
|
2025
Q4 | $8.54M | Buy |
207,246
+49,715
| +32% | +$1.93M | ﹤0.01% | 2165 |
|
|
2025
Q3 | $6.2M | Sell |
157,531
-2,784
| -2% | -$71.1K | ﹤0.01% | 2380 |
|
|
2025
Q2 | $2.99M | Sell |
160,315
-75,218
| -32% | -$1.41M | ﹤0.01% | 2770 |
|
|
2025
Q1 | $4.27M | Sell |
235,533
-9,990
| -4% | -$220K | ﹤0.01% | 2504 |
|
|
2024
Q4 | $5.35M | Buy |
245,523
+42,923
| +21% | +$1.1M | ﹤0.01% | 2466 |
|
|
2024
Q3 | $5.55M | Buy |
202,600
+147,911
| +270% | +$4.12M | ﹤0.01% | 2413 |
|
|
2024
Q2 | $1.42M | Buy |
54,689
+36,198
| +196% | +$870K | ﹤0.01% | 3086 |
|
|
2024
Q1 | $555K | Buy |
18,491
+3,190
| +21% | +$69.3K | ﹤0.01% | 3531 |
|
|
2023
Q4 | $159K | Buy |
+15,301
| New | +$169K | ﹤0.01% | 3973 |
|
|
2023
Q3 | – | Sell |
-4,466
| Closed | -$54.2K | – | 4487 |
|
|
2023
Q2 | $54.2K | Sell |
4,466
-1,617
| -27% | -$18.4K | ﹤0.01% | 4206 |
|
|
2023
Q1 | $77.4K | Buy |
6,083
+670
| +12% | +$7.42K | ﹤0.01% | 4146 |
|
|
2022
Q4 | $34.2K | Hold |
5,413
| – | – | ﹤0.01% | 4378 |
|
|
2022
Q3 | $122K | Buy |
5,413
+27
| +0.5% | +$739 | ﹤0.01% | 4048 |
|
|
2022
Q2 | $103K | Sell |
5,386
-12,992
| -71% | -$321K | ﹤0.01% | 4155 |
|
|
2022
Q1 | $853K | Sell |
18,378
-952
| -5% | -$52K | ﹤0.01% | 3502 |
|
|
2021
Q4 | $1.37M | Buy |
19,330
+430
| +2% | +$43.2K | ﹤0.01% | 3410 |
|
|
2021
Q3 | $2.2M | Sell |
18,900
-1,020
| -5% | -$119K | ﹤0.01% | 3235 |
|
|
2021
Q2 | $3.12M | Buy |
19,920
+3,859
| +24% | +$709K | ﹤0.01% | 3128 |
|
|
2021
Q1 | $3.04M | Sell |
16,061
-2,293
| -12% | -$386K | ﹤0.01% | 3030 |
|
|
2020
Q4 | $2.3M | Sell |
18,354
-16
| -0.1% | -$1.81K | ﹤0.01% | 3127 |
|
|
2020
Q3 | $2M | Buy |
18,370
+2,005
| +12% | +$238K | ﹤0.01% | 3060 |
|
|
2020
Q2 | $1.97M | Buy |
16,365
+2,091
| +15% | +$295K | ﹤0.01% | 3052 |
|
|
2020
Q1 | $1.43M | Sell |
14,274
-139
| -1% | -$25.8K | ﹤0.01% | 3037 |
|
|
2019
Q4 | $3.5M | Sell |
14,413
-262
| -2% | -$49K | ﹤0.01% | 2797 |
|
|
2019
Q3 | $2.41M | Buy |
14,675
+3,250
| +28% | +$617K | ﹤0.01% | 3001 |
|
|
2019
Q2 | $2.7M | Buy |
11,425
+1,663
| +17% | +$411K | ﹤0.01% | 2896 |
|
|
2019
Q1 | $2.57M | Buy |
9,762
+5,611
| +135% | +$968K | ﹤0.01% | 2923 |
|
|
2018
Q4 | $378K | Buy |
4,151
+743
| +22% | +$101K | ﹤0.01% | 3620 |
|
|
2018
Q3 | $655K | Buy |
3,408
+2,579
| +311% | +$543K | ﹤0.01% | 3580 |
|
|
2018
Q2 | $179K | Buy |
+829
| New | +$187K | ﹤0.01% | 3890 |
|
Other funds holding DNTH
APM
RCM
FFM
VCM
OCA
TCM
Northern Trust's DNTH Position: Q1 2026 in Review
Northern Trust increased its Dianthus Therapeutics (DNTH) stake by 47% in Q1 2026, buying an estimated $5.59M and bringing the position to 303,752 shares worth $25.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1517.
Northern Trust first reported a position in DNTH in Q2 2018 and has held it in 31 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.
- Northern Trust held 303,752 shares of Dianthus Therapeutics worth $25.5M as of Q1 2026.
- Northern Trust bought 96,506 Dianthus Therapeutics shares in Q1 2026, an estimated $5.59M.
- Dianthus Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #1517 holding.
- Northern Trust first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 31 quarters since.
- 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.
Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.